Marcus Schindler
Boehringer Ingelheim
42 Papers
565 Citations
Marcus Schindler is an academic researcher from Boehringer Ingelheim. The author has contributed to research in topics: Receptor & Calcitonin gene-related peptide. The author has an hindex of 16, co-authored 41 publications.
Chat about Author
Papers
CL/RAMP2 and CL/RAMP3 produce pharmacologically distinct adrenomedullin receptors: a comparison of effects of adrenomedullin22-52, CGRP8-37 and BIBN4096BS.
Debbie L. Hay,Debbie L. Hay,Stephen G Howitt,Alex C. Conner,Marcus Schindler,David M. Smith,David R. Poyner +6 more
TL;DR: It is shown that on CL/RAMP complexes, AM22–52 has significant selectivity for the CL/rAMP2 combination over the CL-RAMP3 combination, and on the mixed species receptor, CGRP8–37 showed the opposite selectivity.
Patent
Alkyne compounds with mch antagonistic activity and medicaments comprising these compounds
Dirk Stenkamp,Stephan Georg Mueller,Philipp Lustenberger,Thorsten Lehmann-Lintz,Gerald Juergen Roth,Klaus Rudolf,Marcus Schindler,Leo Thomas,Ralf Lotz +8 more
- 13 Apr 2005
TL;DR: Alkyne compounds having MCH-receptor antagonistic activity are useful for preparing pharmaceutical compositions for the treatment of metabolic disorders and/or eating disorders, particularly obesity and diabetes as mentioned in this paper.
68
A key role for transmembrane prolines in calcitonin receptor-like receptor agonist binding and signalling: implications for family B G-protein-coupled receptors.
Alex C. Conner,Debbie L. Hay,Debbie L. Hay,Debbie L. Hay,John Simms,Stephen G Howitt,Marcus Schindler,David M. Smith,Mark Wheatley,David R. Poyner +9 more
TL;DR: Modeling suggested that Pro321 induces a bend in helix 6, bringing its C terminus near that of helix 3, as seen in many family A GPCRs, and is required for agonist binding and receptor activation.
68
A comparison of the actions of BIBN4096BS and CGRP8–37 on CGRP and adrenomedullin receptors expressed on SK-N-MC, L6, Col 29 and Rat 2 cells
TL;DR: BIBN4096BS shows selectivity for the human CRLR/RAMP1 combination compared to the rat counterpart, which may explain its apparent ‘non‐competive’ behaviour.
66
Development and potential of non-peptide antagonists for calcitonin-gene-related peptide (CGRP) receptors: evidence for CGRP receptor heterogeneity.
TL;DR: BIBN4096BS, the first non-peptide CGRP antagonist, is developed, which has sub-nanomolar affinity for primate C GRP receptors, and reveals additional functional differences between the actions of alpha CgrP and beta CGRp.
48